Urovant Sciences Ltd. (UROV) financial statements (2021 and earlier)

Company profile

Business Address 5281 CALIFORNIA AVENUE
IRVINE, CA 92617
State of Incorp.
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
TTM
3/31/2020
3/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments715185
Cash and cash equivalents715185
Restricted cash and investments000
Receivables 0 
Other undisclosed current assets15613
Total current assets:865899
Noncurrent Assets
Operating lease, right-of-use asset43
Property, plant and equipment211
Intangible assets, net (including goodwill)14  
Intangible assets, net (excluding goodwill)14  
Restricted cash and investments211
Other undisclosed noncurrent assets100
Total noncurrent assets:2352
TOTAL ASSETS:10963100
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities392312
Accounts payable422
Accrued liabilities352210
Debt 0 
Deferred compensation liability17 
Due to related parties 00
Other undisclosed current liabilities1  
Total current liabilities:403112
Noncurrent Liabilities
Long-term debt and lease obligation4314
Long-term debt, excluding current maturities  14
Operating lease, liability43
Liabilities, other than long-term debt21087 
Deferred compensation liability, classified10 
Due to related parties20987 
Total noncurrent liabilities:2149014
Total liabilities:25512125
Stockholders' equity
Stockholders' equity attributable to parent(146)(58)75
Common stock000
Common stock, share subscribed but unissued, subscriptions receivable(0)(0)(0)
Additional paid in capital289264250
Accumulated other comprehensive income (loss)(0)00
Accumulated deficit(435)(322)(176)
Total stockholders' equity:(146)(58)75
TOTAL LIABILITIES AND EQUITY:10963100

Income statement (P&L) ($ in millions)

12/31/2020
TTM
3/31/2020
3/31/2019
Operating expenses(165)(139)(111)
Operating loss:(165)(139)(111)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
0(0)(0)
Interest and debt expense (4) 
Other undisclosed loss from continuing operations before equity method investments, income taxes(4)  
Loss from continuing operations before equity method investments, income taxes:(169)(143)(111)
Other undisclosed loss from continuing operations before income taxes(8)(4)(0)
Loss from continuing operations before income taxes:(177)(147)(111)
Income tax expense (benefit)0(0)(0)
Net loss available to common stockholders, diluted:(177)(147)(111)

Comprehensive Income ($ in millions)

12/31/2020
TTM
3/31/2020
3/31/2019
Net loss:(177)(147)(111)
Comprehensive loss:(177)(147)(111)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)00
Comprehensive loss, net of tax, attributable to parent:(177)(147)(111)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: